PepGen Inc Dossier
Outlook & Key Dates
Estimates, guidance, catalysts, and upcoming events
Analyst Estimates Learn more →
5-Yr Fwd EPS Growth
21.6%projected annual EPS growth
Analyst Coverage
8analysts covering
FY EPS (est.)
-$1.14next fiscal year
Monitoring Framework
Key Performance Indicators
FREEDOM2-DM1 10 mg/kg MAD Cohort Enrollment Status Quarterly8.0Target: Fully Enrolled
Cash Runway (Years of Funding) Quarterly1.5Target: Funding into 2H 2027
Watch Items
- FDA Partial Clinical Hold on FREEDOM2-DM1 StudyTrigger: FDA formal response or clearance to proceed with US sitesAction: Submit additional preclinical and clinical analyses to address mouse-specific blood pressure concerns.
- FREEDOM2-DM1 10 mg/kg MAD Cohort Topline Data ReadoutTrigger: Topline data release in 2H 2026Action: Evaluate splicing correction levels and safety profile to support progression to 12.5 mg/kg cohort.
Research as of 19 Jun 2026